NBIX
Neurocrine Biosciences, Inc.NASDAQHealthcare$131.60-0.72%ClosedMarket Cap: $13.21B
As of 2026-04-06
Valuation
P/E (TTM)
27.60
PEG
0.69
P/B
4.03
P/S
4.62
EV/EBITDA
17.95
DCF Value
$508.44
FCF Yield
5.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.2%
Operating Margin
21.6%
Net Margin
16.7%
ROE
16.7%
ROA
10.3%
ROIC
10.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $805.5M | 97.8% | $210.9M | $153.7M | $1.48 | — |
| FY 2025 | $2.86B | 98.2% | $619.1M | $478.6M | $4.67 | — |
| Q3 2025 | $794.9M | 98.2% | $239.0M | $209.5M | $2.04 | — |
| Q2 2025 | $687.5M | 98.4% | $145.6M | $107.5M | $1.06 | — |
| Q1 2025 | $572.6M | 98.4% | $23.6M | $7.9M | $0.08 | — |
| Q4 2024 | $627.7M | 98.5% | $142.0M | $103.1M | $1.00 | — |
| FY 2024 | $2.36B | 98.6% | $570.5M | $341.3M | $3.29 | — |
| Q3 2024 | $622.1M | 98.7% | $183.8M | $129.8M | $1.24 | — |
| Q2 2024 | $590.2M | 98.4% | $145.4M | $65.0M | $0.63 | — |
| Q1 2024 | $515.3M | 98.5% | $99.3M | $43.4M | $0.42 | — |
| Q4 2023 | $515.2M | 98.4% | $150.3M | $147.7M | $1.44 | — |
| FY 2023 | $1.89B | 97.9% | $250.9M | $249.7M | $2.47 | — |